Do analysts rate MBRX or TAOX?

Moleculin Biotech currently has a consensus target price of $3.00, suggesting a potential upside of 589.34%. Given Moleculin Biotech's stronger consensus rating and higher possible upside, analysts plainly believe Moleculin Biotech is more favorable than Synaptogenix. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Moleculin Biotech 1 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.33 Synaptogenix 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Does the media refer more to MBRX or TAOX?

In the previous week, Synaptogenix had 1 more articles in the media than Moleculin Biotech. MarketBeat recorded 3 mentions for Synaptogenix and 2 mentions for Moleculin Biotech. Moleculin Biotech's average media sentiment score of 0.60 beat Synaptogenix's score of 0.37 indicating that Moleculin Biotech is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Moleculin Biotech 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Synaptogenix 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts recommend MBRX or SCLX?

Moleculin Biotech presently has a consensus target price of $3.00, indicating a potential upside of 589.34%. Given Moleculin Biotech's stronger consensus rating and higher probable upside, research analysts plainly believe Moleculin Biotech is more favorable than Scilex. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Moleculin Biotech 1 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.33 Scilex 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Is MBRX or SCLX more profitable?

Moleculin Biotech has a net margin of 0.00% compared to Scilex's net margin of -1,414.57%. Scilex's return on equity of 0.00% beat Moleculin Biotech's return on equity. Company Net Margins Return on Equity Return on Assets Moleculin Biotech N/A -143.51% -24.53% Scilex -1,414.57% N/A -147.00%

Does the media favor MBRX or SCLX?

In the previous week, Scilex had 1 more articles in the media than Moleculin Biotech. MarketBeat recorded 3 mentions for Scilex and 2 mentions for Moleculin Biotech. Moleculin Biotech's average media sentiment score of 0.60 beat Scilex's score of 0.36 indicating that Moleculin Biotech is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Moleculin Biotech 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Scilex 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts recommend MBRX or UG?

Moleculin Biotech currently has a consensus price target of $3.00, suggesting a potential upside of 589.34%. Given Moleculin Biotech's stronger consensus rating and higher probable upside, analysts clearly believe Moleculin Biotech is more favorable than United-Guardian. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Moleculin Biotech 1 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.33 United-Guardian 0 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00

Does the media favor MBRX or UG?

In the previous week, United-Guardian had 1 more articles in the media than Moleculin Biotech. MarketBeat recorded 3 mentions for United-Guardian and 2 mentions for Moleculin Biotech. United-Guardian's average media sentiment score of 0.94 beat Moleculin Biotech's score of 0.60 indicating that United-Guardian is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Moleculin Biotech 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive United-Guardian 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has preferable earnings and valuation, MIRA or MBRX?

MIRA Pharmaceuticals is trading at a lower price-to-earnings ratio than Moleculin Biotech, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio MIRA Pharmaceuticals N/A N/A -$10.44M -$1.24 N/A Moleculin Biotech N/A N/A -$33.56M -$7.13 N/A

Is MIRA or MBRX more profitable?

MIRA Pharmaceuticals' return on equity of -106.95% beat Moleculin Biotech's return on equity. Company Net Margins Return on Equity Return on Assets MIRA Pharmaceuticals N/A -106.95% -104.18% Moleculin Biotech N/A -143.51% -24.53%

Do analysts recommend MBRX or VIRI?

Moleculin Biotech presently has a consensus target price of $3.00, indicating a potential upside of 589.34%. Given Moleculin Biotech's stronger consensus rating and higher possible upside, equities research analysts plainly believe Moleculin Biotech is more favorable than Virios Therapeutics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Moleculin Biotech 1 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.33 Virios Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Which has higher earnings & valuation, MBRX or VIRI?

Virios Therapeutics is trading at a lower price-to-earnings ratio than Moleculin Biotech, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Moleculin Biotech N/A N/A -$33.56M -$7.13 N/A Virios Therapeutics N/A N/A -$5.30M -$0.27 N/A

Is MBRX or VIRI more profitable?

Virios Therapeutics' return on equity of -130.33% beat Moleculin Biotech's return on equity. Company Net Margins Return on Equity Return on Assets Moleculin Biotech N/A -143.51% -24.53% Virios Therapeutics N/A -130.33% -115.00%

Does the media refer more to MBRX or VIRI?

In the previous week, Moleculin Biotech had 1 more articles in the media than Virios Therapeutics. MarketBeat recorded 2 mentions for Moleculin Biotech and 1 mentions for Virios Therapeutics. Moleculin Biotech's average media sentiment score of 0.60 beat Virios Therapeutics' score of 0.00 indicating that Moleculin Biotech is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Moleculin Biotech 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Virios Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Moleculin Biotech (MBRX) Competitors

$0.41 -0.02 (-5.33%)

As of 02:53 PM Eastern

Compare

MBRX vs. TAOX, SCLX, UG, MIRA, and VIRI

Should you buy Moleculin Biotech stock or one of its competitors? Moleculin Biotech's main competitors and comparable companies include Synaptogenix (TAOX), Scilex (SCLX), United-Guardian (UG), MIRA Pharmaceuticals (MIRA), and Virios Therapeutics (VIRI). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does Moleculin Biotech compare to Synaptogenix?

Moleculin Biotech (NASDAQ:MBRX) and Synaptogenix (NASDAQ:TAOX) are both small-cap healthcare companies, but which is the better business? We will compare the two companies based on the strength of their valuation, media sentiment, risk, analyst recommendations, profitability, institutional ownership, dividends and earnings.

In the previous week, Synaptogenix had 1 more articles in the media than Moleculin Biotech. MarketBeat recorded 3 mentions for Synaptogenix and 2 mentions for Moleculin Biotech. Moleculin Biotech's average media sentiment score of 0.60 beat Synaptogenix's score of 0.37 indicating that Moleculin Biotech is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Moleculin Biotech	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Synaptogenix	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

15.5% of Moleculin Biotech shares are owned by institutional investors. Comparatively, 10.3% of Synaptogenix shares are owned by institutional investors. 18.0% of Moleculin Biotech shares are owned by insiders. Comparatively, 2.7% of Synaptogenix shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Moleculin Biotech has a net margin of 0.00% compared to Synaptogenix's net margin of -2,153.97%. Synaptogenix's return on equity of -128.51% beat Moleculin Biotech's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Moleculin Biotech	N/A	-143.51%	-24.53%
Synaptogenix	-2,153.97%	-128.51%	-97.54%

Synaptogenix has higher revenue and earnings than Moleculin Biotech. Synaptogenix is trading at a lower price-to-earnings ratio than Moleculin Biotech, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Moleculin Biotech	N/A	N/A	-$33.56M	-$7.13	N/A
Synaptogenix	$300K	96.29	-$28.74M	-$3.85	N/A

Moleculin Biotech currently has a consensus target price of $3.00, suggesting a potential upside of 589.34%. Given Moleculin Biotech's stronger consensus rating and higher possible upside, analysts plainly believe Moleculin Biotech is more favorable than Synaptogenix.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Moleculin Biotech	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33
Synaptogenix	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Moleculin Biotech has a beta of 2, suggesting that its share price is 100% more volatile than the broader market. Comparatively, Synaptogenix has a beta of 1.73, suggesting that its share price is 73% more volatile than the broader market.

Summary

Moleculin Biotech beats Synaptogenix on 9 of the 14 factors compared between the two stocks.

How does Moleculin Biotech compare to Scilex?

Moleculin Biotech (NASDAQ:MBRX) and Scilex (NASDAQ:SCLX) are both small-cap healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their institutional ownership, analyst recommendations, risk, profitability, media sentiment, dividends, valuation and earnings.

Moleculin Biotech has a net margin of 0.00% compared to Scilex's net margin of -1,414.57%. Scilex's return on equity of 0.00% beat Moleculin Biotech's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Moleculin Biotech	N/A	-143.51%	-24.53%
Scilex	-1,414.57%	N/A	-147.00%

Moleculin Biotech presently has a consensus target price of $3.00, indicating a potential upside of 589.34%. Given Moleculin Biotech's stronger consensus rating and higher probable upside, research analysts plainly believe Moleculin Biotech is more favorable than Scilex.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Moleculin Biotech	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33
Scilex	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Moleculin Biotech has higher earnings, but lower revenue than Scilex. Moleculin Biotech is trading at a lower price-to-earnings ratio than Scilex, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Moleculin Biotech	N/A	N/A	-$33.56M	-$7.13	N/A
Scilex	$30.25M	0.81	-$358.73M	-$49.70	N/A

Moleculin Biotech has a beta of 2, meaning that its share price is 100% more volatile than the broader market. Comparatively, Scilex has a beta of 1.72, meaning that its share price is 72% more volatile than the broader market.

In the previous week, Scilex had 1 more articles in the media than Moleculin Biotech. MarketBeat recorded 3 mentions for Scilex and 2 mentions for Moleculin Biotech. Moleculin Biotech's average media sentiment score of 0.60 beat Scilex's score of 0.36 indicating that Moleculin Biotech is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Moleculin Biotech	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Scilex	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

15.5% of Moleculin Biotech shares are owned by institutional investors. Comparatively, 69.7% of Scilex shares are owned by institutional investors. 18.0% of Moleculin Biotech shares are owned by company insiders. Comparatively, 4.5% of Scilex shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Summary

Moleculin Biotech beats Scilex on 10 of the 14 factors compared between the two stocks.

How does Moleculin Biotech compare to United-Guardian?

Moleculin Biotech (NASDAQ:MBRX) and United-Guardian (NASDAQ:UG) are both small-cap healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their earnings, risk, valuation, dividends, institutional ownership, profitability, analyst recommendations and media sentiment.

United-Guardian has higher revenue and earnings than Moleculin Biotech. Moleculin Biotech is trading at a lower price-to-earnings ratio than United-Guardian, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Moleculin Biotech	N/A	N/A	-$33.56M	-$7.13	N/A
United-Guardian	$10.55M	2.98	$2.11M	$0.54	12.70

United-Guardian has a net margin of 22.01% compared to Moleculin Biotech's net margin of 0.00%. United-Guardian's return on equity of 22.24% beat Moleculin Biotech's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Moleculin Biotech	N/A	-143.51%	-24.53%
United-Guardian	22.01%	22.24%	19.12%

Moleculin Biotech currently has a consensus price target of $3.00, suggesting a potential upside of 589.34%. Given Moleculin Biotech's stronger consensus rating and higher probable upside, analysts clearly believe Moleculin Biotech is more favorable than United-Guardian.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Moleculin Biotech	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33
United-Guardian	0 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00

Moleculin Biotech has a beta of 2, meaning that its share price is 100% more volatile than the broader market. Comparatively, United-Guardian has a beta of 0.95, meaning that its share price is 5% less volatile than the broader market.

In the previous week, United-Guardian had 1 more articles in the media than Moleculin Biotech. MarketBeat recorded 3 mentions for United-Guardian and 2 mentions for Moleculin Biotech. United-Guardian's average media sentiment score of 0.94 beat Moleculin Biotech's score of 0.60 indicating that United-Guardian is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Moleculin Biotech	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
United-Guardian	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

15.5% of Moleculin Biotech shares are held by institutional investors. Comparatively, 23.2% of United-Guardian shares are held by institutional investors. 18.0% of Moleculin Biotech shares are held by company insiders. Comparatively, 29.0% of United-Guardian shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Summary

United-Guardian beats Moleculin Biotech on 10 of the 14 factors compared between the two stocks.

How does Moleculin Biotech compare to MIRA Pharmaceuticals?

MIRA Pharmaceuticals (NASDAQ:MIRA) and Moleculin Biotech (NASDAQ:MBRX) are both small-cap healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their earnings, profitability, analyst recommendations, valuation, institutional ownership, media sentiment, risk and dividends.

MIRA Pharmaceuticals' return on equity of -106.95% beat Moleculin Biotech's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
MIRA Pharmaceuticals	N/A	-106.95%	-104.18%
Moleculin Biotech	N/A	-143.51%	-24.53%

35.2% of MIRA Pharmaceuticals shares are held by institutional investors. Comparatively, 15.5% of Moleculin Biotech shares are held by institutional investors. 19.9% of MIRA Pharmaceuticals shares are held by insiders. Comparatively, 18.0% of Moleculin Biotech shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

MIRA Pharmaceuticals is trading at a lower price-to-earnings ratio than Moleculin Biotech, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
MIRA Pharmaceuticals	N/A	N/A	-$10.44M	-$1.24	N/A
Moleculin Biotech	N/A	N/A	-$33.56M	-$7.13	N/A

In the previous week, Moleculin Biotech had 1 more articles in the media than MIRA Pharmaceuticals. MarketBeat recorded 2 mentions for Moleculin Biotech and 1 mentions for MIRA Pharmaceuticals. MIRA Pharmaceuticals' average media sentiment score of 1.82 beat Moleculin Biotech's score of 0.60 indicating that MIRA Pharmaceuticals is being referred to more favorably in the media.

Company	Overall Sentiment
MIRA Pharmaceuticals	Very Positive
Moleculin Biotech	Positive

MIRA Pharmaceuticals presently has a consensus price target of $3.50, suggesting a potential upside of 425.21%. Moleculin Biotech has a consensus price target of $3.00, suggesting a potential upside of 589.34%. Given Moleculin Biotech's higher probable upside, analysts plainly believe Moleculin Biotech is more favorable than MIRA Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
MIRA Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33
Moleculin Biotech	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33

MIRA Pharmaceuticals has a beta of 1.48, suggesting that its share price is 48% more volatile than the broader market. Comparatively, Moleculin Biotech has a beta of 2, suggesting that its share price is 100% more volatile than the broader market.

Summary

MIRA Pharmaceuticals beats Moleculin Biotech on 6 of the 10 factors compared between the two stocks.

How does Moleculin Biotech compare to Virios Therapeutics?

Moleculin Biotech (NASDAQ:MBRX) and Virios Therapeutics (NASDAQ:VIRI) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their risk, earnings, institutional ownership, profitability, dividends, analyst recommendations, media sentiment and valuation.

15.5% of Moleculin Biotech shares are owned by institutional investors. Comparatively, 9.1% of Virios Therapeutics shares are owned by institutional investors. 18.0% of Moleculin Biotech shares are owned by insiders. Comparatively, 12.2% of Virios Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Virios Therapeutics' return on equity of -130.33% beat Moleculin Biotech's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Moleculin Biotech	N/A	-143.51%	-24.53%
Virios Therapeutics	N/A	-130.33%	-115.00%

Moleculin Biotech presently has a consensus target price of $3.00, indicating a potential upside of 589.34%. Given Moleculin Biotech's stronger consensus rating and higher possible upside, equities research analysts plainly believe Moleculin Biotech is more favorable than Virios Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Moleculin Biotech	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33
Virios Therapeutics	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Virios Therapeutics is trading at a lower price-to-earnings ratio than Moleculin Biotech, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Moleculin Biotech	N/A	N/A	-$33.56M	-$7.13	N/A
Virios Therapeutics	N/A	N/A	-$5.30M	-$0.27	N/A

In the previous week, Moleculin Biotech had 1 more articles in the media than Virios Therapeutics. MarketBeat recorded 2 mentions for Moleculin Biotech and 1 mentions for Virios Therapeutics. Moleculin Biotech's average media sentiment score of 0.60 beat Virios Therapeutics' score of 0.00 indicating that Moleculin Biotech is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Moleculin Biotech	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Virios Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Moleculin Biotech has a beta of 2, indicating that its share price is 100% more volatile than the broader market. Comparatively, Virios Therapeutics has a beta of 1.58, indicating that its share price is 58% more volatile than the broader market.

Summary

Moleculin Biotech beats Virios Therapeutics on 9 of the 12 factors compared between the two stocks.

Get Moleculin Biotech News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding MBRX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

MBRX vs. The Competition

Export

Metric	Moleculin Biotech	Pharmaceuticals Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$7.99M	$12.42B	$7.27B	$12.97B
Dividend Yield	N/A	2.63%	2.51%	22.89%
P/E Ratio	-0.06	807.81	275.40	25.37
Price / Sales	N/A	748.45	562.29	78.82
Price / Cash	N/A	86.65	77.16	53.04
Price / Book	0.09	9.21	10.55	5.95
Net Income	-$33.56M	$2.84B	$3.50B	$380.75M
7 Day Performance	-6.58%	-4.00%	-3.92%	-3.96%
1 Month Performance	-47.11%	-8.07%	-8.30%	-6.81%
1 Year Performance	-96.69%	-5.86%	2.35%	-4.58%

Moleculin Biotech Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
MBRX Moleculin Biotech	3.6938 of 5 stars	$0.41 -5.3%	$3.00 +628.2%	-96.3%	$8.03M	N/A	N/A	17	Gap Up
TAOX Synaptogenix	0.1522 of 5 stars	$3.96 -13.2%	N/A	-61.4%	$34.12M	$300K	N/A	4
SCLX Scilex	0.4008 of 5 stars	$3.49 -11.9%	N/A	-80.5%	$33.63M	$30.25M	N/A	34	News Coverage High Trading Volume
UG United-Guardian	2.3081 of 5 stars	$7.09 -1.2%	N/A	-8.5%	$32.99M	$10.55M	13.13	25	Short Interest Decrease High Trading Volume
MIRA MIRA Pharmaceuticals	3.0123 of 5 stars	$0.71 -0.3%	$3.50 +393.0%	-48.1%	$29.91M	N/A	N/A	2	Positive News

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:MBRX) was last updated on 10/14/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Moleculin Biotech (MBRX) Competitors

MBRX vs. TAOX, SCLX, UG, MIRA, and VIRI

How does Moleculin Biotech compare to Synaptogenix?

Summary

How does Moleculin Biotech compare to Scilex?

Summary

How does Moleculin Biotech compare to United-Guardian?

Summary

How does Moleculin Biotech compare to MIRA Pharmaceuticals?

Summary

How does Moleculin Biotech compare to Virios Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

MBRX vs. The Competition

Moleculin Biotech Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Moleculin Biotech (MBRX) Competitors

MBRX vs. TAOX, SCLX, UG, MIRA, and VIRI

How does Moleculin Biotech compare to Synaptogenix?

Does the media refer more to MBRX or TAOX?

Do insiders & institutionals hold more shares of MBRX or TAOX?

Is MBRX or TAOX more profitable?

Which has better valuation & earnings, MBRX or TAOX?

Do analysts rate MBRX or TAOX?

Which has more volatility and risk, MBRX or TAOX?

Summary

How does Moleculin Biotech compare to Scilex?

Is MBRX or SCLX more profitable?

Do analysts recommend MBRX or SCLX?

Which has better earnings & valuation, MBRX or SCLX?

Which has more risk and volatility, MBRX or SCLX?

Does the media favor MBRX or SCLX?

Do institutionals & insiders believe in MBRX or SCLX?

Summary

How does Moleculin Biotech compare to United-Guardian?

Which has preferable valuation and earnings, MBRX or UG?

Is MBRX or UG more profitable?

Do analysts recommend MBRX or UG?

Which has more risk & volatility, MBRX or UG?

Does the media favor MBRX or UG?

Do institutionals and insiders hold more shares of MBRX or UG?

Summary

How does Moleculin Biotech compare to MIRA Pharmaceuticals?

Is MIRA or MBRX more profitable?

Do insiders & institutionals hold more shares of MIRA or MBRX?

Which has preferable earnings and valuation, MIRA or MBRX?

Does the media prefer MIRA or MBRX?

Do analysts recommend MIRA or MBRX?

Which has more risk and volatility, MIRA or MBRX?

Summary

How does Moleculin Biotech compare to Virios Therapeutics?

Do institutionals and insiders believe in MBRX or VIRI?

Is MBRX or VIRI more profitable?

Do analysts recommend MBRX or VIRI?

Which has higher earnings & valuation, MBRX or VIRI?

Does the media refer more to MBRX or VIRI?

Which has more volatility and risk, MBRX or VIRI?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

MBRX vs. The Competition

Moleculin Biotech Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools